Prognosis Prediction of Cardiovascular Event With Glucose‐Albumin Ratio on Patients With Cancer and Prescribed With Anthracycline
GAR is a potential biomarker for predicting the prognosis of cancer patients undergoing anthracycline-based chemotherapy. Monitoring GAR levels before and during treatment may help identify patients at higher risk of adverse outcomes, facilitating personalized treatment strategies and improving clinical management.
Authors
- Mei‐Zhen Wu
- Q W Ren (ORCID: https://orcid.org/0000-0003-0712-9299)
- Xu Zhu (ORCID: https://orcid.org/0000-0002-4347-3639)
- Hung‐Fat Tse (ORCID: https://orcid.org/0000-0002-9578-7808)
- Iokfai Cheang (ORCID: https://orcid.org/0000-0002-9950-9696)
- Xinli Li (ORCID: https://orcid.org/0000-0002-6794-1468)
- Xin Xu (ORCID: https://orcid.org/0000-0001-6795-4296)
- Ziqi Chen (ORCID: https://orcid.org/0000-0002-2103-861X)
- Ying Li (ORCID: https://orcid.org/0000-0002-0438-449X)
- Kai‐Hang Yiu
Institutions
- Queen Mary Hospital (CN)
- University of Hong Kong - Shenzhen Hospital (CN)
- Jiangsu Province Hospital (CN)
- Nanjing Medical University (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/cam4.70471
- Citations
- 1
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.40
Funders
- National Natural Science Foundation of China
- Nanjing Medical University
- Collaborative Innovation Center for Cardiovascular Disease Translational Medicine
- Sanming Project of Medicine in Shenzhen